C16 Biosciences has introduced a precision-fermented cocoa butter equivalent under its Palmless brand, marking its first food ingredient, according to vegconomist. The New York company launched it alongside additions to its personal-care portfolio.
C16 says the fat is designed to give chocolate manufacturers more consistent crystallization and sensory performance than agricultural cocoa butter, whose properties can change across origins and harvests, vegconomist reported. The company also argues that fermentation could reduce exposure to disruptions and unstable pricing in cocoa supply.
The expansion brings Palmless to five commercial ingredients, according to vegconomist. C16 told the publication that its ingredients are manufactured in 50,000-litre fermentation vessels, a capacity it first attained in 2022. Founder and CEO Shara Ticku said the process can produce fats more closely matched to manufacturers’ specifications.
A separate Investment Climate Podcast report syndicated by vegconomist highlights an upstream obstacle for fermentation businesses. Saku Biosciences says its PicoShells platform screens large numbers of strains under bioreactor conditions rather than relying solely on laboratory performance. The company’s CEO, Mark van Zee, recently closed a $940,000 SAFE round led institutionally by Big Idea Ventures, according to the podcast. Saku presents its technology as a way to reduce failed scale-up work and help fermented ingredients approach cost parity with established inputs.
CONCLUSION C16’s launch shows fermentation moving further into functional fats for food, while Saku’s work addresses the manufacturing economics behind such products. The next points to watch are commercial uptake of the cocoa butter equivalent and whether bioreactor-based strain selection delivers the scale-up improvements Saku describes.